FUSION PROTEINS WITH SPECIFICITY FOR ED-B AND LONG SERUM HALF-LIFE FOR DIAGNOSIS OR TREATMENT OF CANCER

The invention relates to fusion proteins comprising at least one extradomain B of fibronectin (ED-B) specific binding domain with high stability in serum and at least one APS domain essentially consisting of or consisting of up to about 80 amino acids selected from alanine, proline, serine, and opti...

Full description

Saved in:
Bibliographic Details
Main Authors Gloser, Manja, Bosse-Doenecke, Eva, Katzschmann, Anja, Fiedler, Erik, Haupts, Ulrich
Format Patent
LanguageEnglish
Published 17.06.2021
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:The invention relates to fusion proteins comprising at least one extradomain B of fibronectin (ED-B) specific binding domain with high stability in serum and at least one APS domain essentially consisting of or consisting of up to about 80 amino acids selected from alanine, proline, serine, and optionally aspartic acid. The fusion protein further comprises at least one coupling site consisting of at least one cysteine. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications, such as diagnosis or treatment of cancer or cardiovascular diseases.
Bibliography:Application Number: US201816761677